These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. FGF21 in obesity and cancer: New insights. Lu W; Li X; Luo Y Cancer Lett; 2021 Feb; 499():5-13. PubMed ID: 33264641 [TBL] [Abstract][Full Text] [Related]
27. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191 [TBL] [Abstract][Full Text] [Related]
28. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730 [TBL] [Abstract][Full Text] [Related]
29. Role of liver FGF21-KLB signaling in ketogenic diet-induced amelioration of hepatic steatosis. Guo W; Cao H; Shen Y; Li W; Wang W; Cheng L; Cai M; Xu F Nutr Diabetes; 2024 Apr; 14(1):18. PubMed ID: 38609395 [TBL] [Abstract][Full Text] [Related]
30. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Conarello SL; Jiang G; Mu J; Li Z; Woods J; Zycband E; Ronan J; Liu F; Roy RS; Zhu L; Charron MJ; Zhang BB Diabetologia; 2007 Jan; 50(1):142-50. PubMed ID: 17131145 [TBL] [Abstract][Full Text] [Related]
31. Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue. Asrih M; Altirriba J; Rohner-Jeanrenaud F; Jornayvaz FR PLoS One; 2015; 10(5):e0126364. PubMed ID: 25973847 [TBL] [Abstract][Full Text] [Related]
32. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278 [TBL] [Abstract][Full Text] [Related]
33. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271 [TBL] [Abstract][Full Text] [Related]
34. Hepatic FGF21 preserves thermoregulation and cardiovascular function during bacterial inflammation. Huen SC; Wang A; Feola K; Desrouleaux R; Luan HH; Hogg R; Zhang C; Zhang QJ; Liu ZP; Medzhitov R J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34406362 [TBL] [Abstract][Full Text] [Related]
35. Glucagon receptor signaling is not required for Galsgaard KD; Pedersen J; Kjeldsen SAS; Winther-Sørensen M; Stojanovska E; Vilstrup H; Ørskov C; Wewer Albrechtsen NJ; Holst JJ Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G912-G927. PubMed ID: 32174131 [TBL] [Abstract][Full Text] [Related]
36. β-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice. Somm E; Henry H; Bruce SJ; Bonnet N; Montandon SA; Niederländer NJ; Messina A; Aeby S; Rosikiewicz M; Fajas L; Sempoux C; Ferrari SL; Greub G; Pitteloud N Am J Physiol Endocrinol Metab; 2018 Nov; 315(5):E833-E847. PubMed ID: 29944388 [TBL] [Abstract][Full Text] [Related]
37. Identification of a crucial amino acid responsible for the loss of specifying FGFR1-KLB affinity of the iodinated FGF21. Luo W; Lin XM; Wang TX; Cai JL; Zeng XF; Zhu CR; Li RZ; Wang H; Wu XP J Cell Physiol; 2019 Mar; 234(3):2500-2510. PubMed ID: 30317562 [TBL] [Abstract][Full Text] [Related]
38. Liver-secreted FGF21 induces sarcopenia by inhibiting satellite cell myogenesis via klotho beta in decompensated cirrhosis. Zhou D; Shi Y; Zhang D; Zuo J; Zeng C; Mamtawla G; Huang L; Gao X; Zhang L; Wang X Redox Biol; 2024 Oct; 76():103333. PubMed ID: 39226764 [TBL] [Abstract][Full Text] [Related]
39. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313 [TBL] [Abstract][Full Text] [Related]
40. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease. Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]